Remote Monitoring for Cancer Patients Undergoing Chemotherapy

This study is testing a new way to monitor cancer patients receiving chemotherapy using an iPhone app called Locus Health and an Apple Watch. The goal is to see if these devices can help detect health problems early, potentially improving your care and reducing healthcare costs. You could be eligible if you are 18 or older, have a solid tumor or blood cancer (hematological malignancy), are starting a new chemotherapy or chemoimmunotherapy treatment for at least four months, and own an Apple iPhone. The study will be considered successful if patients use the app frequently, find the app and watch easy to use, and few patients drop out. The study aims to enroll 100 participants.

Study design
This is an observational pilot study involving 100 participants, divided into three groups based on how often they receive queries through the Locus Health iPhone app.
What's involved
You will use the Locus Health iPhone App and an Apple Watch during your chemotherapy regimen, for up to 120 days or until your chemotherapy stops.
Compensation
Not stated in the trial record.
Follow-up
Participants will be monitored for up to 120 days or until their chemotherapy regimen has stopped, whichever is sooner.

AI-generated from the public study record. Only the study team can confirm whether you're eligible — confirm details with them before making decisions.

NCT06106360

A Pilot Prospective Clinical Trial Using Remote Monitoring for Cancer Patients Undergoing Outpatient Chemotherapy

Recruiting
Not specifiedAges 18+Observational
Inova Health Care Services
~100 participants
Updated 2025-12-08 on ClinicalTrials.gov
What's tested:Locus Health iPhone App

At a glance

Recruiting sites
1 of 1 listed site is recruiting right now
RecruitingSuspended, closed, or not yet open
What they're measuring
The Use of Locus Heath iPhone App and the Apple Watch by Participants Undergoing Outpatient Chemotherapy.
Measured over 120 days or until the chemotherapy regimen has stopped, whichever is sooner
Solid Tumor
Hematological Malignancy

NCT06106360

Where you'd take part

This study runs at 1 site. They're the same protocol — you choose where, and that choice sets who your contact draft is addressed to.

  • Inova Schar Cancer Institute

    Fairfax, Virginiastudy coordinator listed

    Recruiting

Sites open and close at different times, so the status above is per site — it can differ from the study's overall status.

  • John Deeken, MD · PRINCIPAL_INVESTIGATOR · Inova Schar Cancer Institute

Opens a ready-to-send draft in your own email app — review before sending.

Want this trial checked against your situation?

Add a private profile and we'll compare every criterion below against your situation — and tell you which ones are met, uncertain, or excluding.

Check eligibility for this trial ~2 min · HIPAA-protected · delete anytime
Eligibility criteria

Inclusion

Planned to be treated with a new cytotoxic chemotherapy or chemoimmunotherapy regimen for a solid tumor or malignant hematology condition for at least 4 months
ECOG performance status of 0-2
Age of 18 or older patient with any solid tumor or hematologic malignancy
English or Spanish speaker
Own an Apple iPhone
Capacity and willingness to provide informed consent

Exclusion

Patients undergoing concurrent radiation since they will be seen on a daily basis by clinic care teams and are not likely to benefit from active remote patient monitoring
Patients unwilling or unable to comply with the protocol, including wearing the Apple Watch (including recharging daily) and answering queries on the Locus Health iPhone application per the protocol and study group cadence
Any condition for which in the Investigator's opinion would limit compliance with study requirements
  • The Use of Locus Heath iPhone App and the Apple Watch by Participants Undergoing Outpatient Chemotherapy.120 days or until the chemotherapy regimen has stopped, whichever is sooner

    The feasibility is determined when 80% of the patients wear the watch at least 70% of the time during waking hours.